<![CDATA[Pharma Unscripted]]>Pharma Unscripted explores how evidence is evolving across the biopharma landscape—and what that means for patients, access, and decision-making.

Through expert-led conversations, the series examines how organizations are generating and applying evidence to bring meaningful therapies to the people who need them most.

From patient-centered outcomes and real-world evidence to value demonstration and AI in medical communications, each episode breaks down the trends shaping how therapies move from development to real-world impact.

]]>https://www.rtihs.org/Riverside.fm (https://riverside.com)Tue, 16 Jun 2026 23:09:41 GMTWed, 06 May 2026 14:55:47 GMT60RTI Health Solutions<p><i>Pharma Unscripted</i> explores how evidence is evolving across the biopharma landscape—and what that means for patients, access, and decision-making.<br /></p><p>Through expert-led conversations, the series examines how organizations are generating and applying evidence to bring meaningful therapies to the people who need them most.<br /></p><p>From patient-centered outcomes and real-world evidence to value demonstration and AI in medical communications, each episode breaks down the trends shaping how therapies move from development to real-world impact.</p>episodicRTI Health Solutionsjrees@rti.orgno<![CDATA[The Patient Experience: Evaluating Tolerability in Oncology Treatments]]>Why is patient-centered evidence critical in oncology?

 

As oncology treatments become more targeted and long-term, organizations need evidence that captures real-world patient experience. This episode explores how PROs, tolerability, and patient-centered evidence are shaping adherence, evidence strategy, and market access.

 

 

 

Key Topics:

  • Real-world patient experience
  • Tolerability and treatment burden
  • Patient-reported outcomes (PROs)
  • Patient-centered evidence strategy
  • Adherence and market access

 

Guests:

  • Ari Gnanasakthy, Principal Scientist, Patient-Centered Outcomes Assessment
  • Dawn Odom, Vice President, Biostatistics

 

Learn more about tolerability research

]]>1bc07e52-73d5-43f3-a58a-5cdbaa8b2a7dWed, 03 Jun 2026 15:53:54 GMT<p>Why is patient-centered evidence critical in oncology?</p><p> </p><p>As oncology treatments become more targeted and long-term, organizations need evidence that captures real-world patient experience. This episode explores how PROs, tolerability, and patient-centered evidence are shaping adherence, evidence strategy, and market access.</p><p> </p><p> </p><p> </p><p><b>Key Topics:</b></p><ul><li>Real-world patient experience</li><li>Tolerability and treatment burden</li><li>Patient-reported outcomes (PROs)</li><li>Patient-centered evidence strategy</li><li>Adherence and market access</li></ul><p><b> </b></p><p>Guests:</p><ul><li>Ari Gnanasakthy, Principal Scientist, Patient-Centered Outcomes Assessment</li><li>Dawn Odom, Vice President, Biostatistics</li></ul><p><b> </b></p><p><a rel="noopener noreferrer nofollow" href="https://www.rtihs.org/resource/insight/tolerability-strategic-differentiator-oncology" target="_blank"><b>Learn more about tolerability research</b></a></p>no00:26:0514The Patient Experience: Evaluating Tolerability in Oncology Treatmentsfull<![CDATA[AI in Medical Communications: Why Human Expertise Still Matters]]>This episode is part three of a three-part series featured on Fierce Pharma’s The Top Line podcast.

AI is transforming medical communications, but it’s not replacing human expertise.

In this episode of Pharma Unscripted, we explore how AI is being used across med comms workflows, from literature review to content creation, and where it introduces risk.

Accuracy, context, and scientific integrity remain critical, making human oversight essential in an AI-driven environment.

Key Topics:

  • AI in medical communications
  • Scientific accuracy and governance
  • Risks and limitations of AI-generated content
  • Role of human expertise

Guests:

  • Margaret Mathes, Director of Medical Editing
  • Gabby Dardis, Senior Integrated Evidence Strategist
  • Frances Ramsey, Manager of Library Services
]]>b86510cd-0d70-4692-95f6-372ba77e666bFri, 08 May 2026 19:53:36 GMT<p>This episode is part three of a three-part series featured on Fierce Pharma’s <i>The Top Line </i>podcast.</p><p></p><p>AI is transforming medical communications, but it’s not replacing human expertise.</p><p></p><p>In this episode of <i>Pharma Unscripted</i>, we explore how AI is being used across med comms workflows, from literature review to content creation, and where it introduces risk.</p><p></p><p>Accuracy, context, and scientific integrity remain critical, making human oversight essential in an AI-driven environment.</p><p></p><p><b>Key Topics:</b></p><ul><li>AI in medical communications</li><li>Scientific accuracy and governance</li><li>Risks and limitations of AI-generated content</li><li>Role of human expertise</li></ul><p></p><p>Guests: </p><ul><li>Margaret Mathes, Director of Medical Editing</li><li>Gabby Dardis, Senior Integrated Evidence Strategist</li><li>Frances Ramsey, Manager of Library Services</li></ul>no00:20:3513AI in Medical Communications: Why Human Expertise Still Mattersfull<![CDATA[From Approval to Value: Evidence Storytelling, HEOR & Market Access]]>This episode is part two of a three-part series featured on Fierce Pharma’s The Top Line podcast.

Getting a therapy approved is only part of the journey, demonstrating its value is what drives access.

In this episode of Pharma Unscripted, we explore how evidence storytelling is becoming critical in biopharma. From real-world evidence (RWE) to health economics and outcomes research (HEOR), organizations must translate complex data into clear, decision-relevant insights.

As payers and HTA bodies demand stronger value demonstration, how you communicate evidence can directly impact patient access.

Key Topics:

  • Evidence storytelling in biopharma
  • HEOR and real-world evidence (RWE)
  • Value communication for payers and HTAs
  • Market access strategy

Guests:

  • Kate Lothman, Director of Medical Writing & Publications
  • Sara Musetti Jenkins, Principal Medical Writer
  • Jason Crouch, Graphic Designer
]]>9b553a66-4c70-46ff-9360-fd6a5f7ef07dFri, 08 May 2026 19:52:03 GMT<p>This episode is part two of a three-part series featured on Fierce Pharma’s <i>The Top Line </i>podcast.</p><p></p><p>Getting a therapy approved is only part of the journey, demonstrating its value is what drives access.</p><p></p><p>In this episode of <i>Pharma Unscripted</i>, we explore how evidence storytelling is becoming critical in biopharma. From real-world evidence (RWE) to health economics and outcomes research (HEOR), organizations must translate complex data into clear, decision-relevant insights.</p><p></p><p>As payers and HTA bodies demand stronger value demonstration, how you communicate evidence can directly impact patient access.</p><p></p><p><b>Key Topics:</b></p><ul><li>Evidence storytelling in biopharma</li><li>HEOR and real-world evidence (RWE)</li><li>Value communication for payers and HTAs</li><li>Market access strategy</li></ul><p></p><p>Guests:</p><ul><li>Kate Lothman, Director of Medical Writing &amp; Publications</li><li>Sara Musetti Jenkins, Principal Medical Writer</li><li>Jason Crouch, Graphic Designer</li></ul>no00:17:4112From Approval to Value: Evidence Storytelling, HEOR & Market Accessfull<![CDATA[Putting Patients First: Patient-Centered Evidence & PROs in Biopharma]]>This episode is part one of a three-part series featured on Fierce Pharma’s The Top Line podcast.

What does it really mean to put patients first in biopharma?

In this episode of Pharma Unscripted, we explore how patient-centered evidence, including patient-reported outcomes (PROs), is reshaping clinical development, regulatory expectations, and market access.

As decision-makers look beyond traditional endpoints, understanding the real patient experience, quality of life, treatment burden, and daily impact, is becoming essential.

Key Topics:

  • Patient-reported outcomes (PROs)
  • Patient-centered evidence generation
  • Clinical trial design and endpoints
  • Market access and patient experience

Guests:

  • Ash Menon, Sr. Medical Affairs Lead
  • Mark Price, Head of Expert Perspectives
]]>9d8124ed-0a31-4e23-8431-53b4503bdeb6Fri, 08 May 2026 19:50:24 GMT<p>This episode is part one of a three-part series featured on Fierce Pharma’s <i>The Top Line </i>podcast.</p><p></p><p>What does it really mean to put patients first in biopharma?</p><p></p><p>In this episode of <i>Pharma Unscripted</i>, we explore how patient-centered evidence, including patient-reported outcomes (PROs), is reshaping clinical development, regulatory expectations, and market access.</p><p></p><p>As decision-makers look beyond traditional endpoints, understanding the real patient experience, quality of life, treatment burden, and daily impact, is becoming essential.</p><p></p><p><b>Key Topics:</b></p><ul><li>Patient-reported outcomes (PROs)</li><li>Patient-centered evidence generation</li><li>Clinical trial design and endpoints</li><li>Market access and patient experience</li></ul><p></p><p>Guests: </p><ul><li>Ash Menon, Sr. Medical Affairs Lead</li><li>Mark Price, Head of Expert Perspectives</li></ul>no00:28:0311Putting Patients First: Patient-Centered Evidence & PROs in Biopharmafull